Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination (Q82276734)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

8

Otfried Kistner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

3

Helga Savidis Dacho

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

7

P Noel Barrett

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

André van Maurik

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Peter Brühl

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Michael Schwendinger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Brian A Crowe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Keith Howard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

16 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1778-1785

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

Seasonal inactivated influenza virus vaccines

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Selection of influenza vaccine strains and developing pandemic vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

CD4+ T-cell induction and effector functions: a comparison of immunity against soluble antigens and viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Origin and evolution of influenza virus hemagglutinin genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

inferred from DOI database lookup

7 January 2021

based on heuristic

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.12.008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20018265%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference